Real-World Testing Practices, Treatment Patterns and Clinical Outcomes in Patients from Central Eastern Europe with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Retrospective Chart Review Study (REFLECT)

被引：7

作者：

Janzic, Urska ^{[1
]}

Turnsek, Nina ^{[2
]}

Dediu, Mircea ^{[3
]}

Donev, Ivan Shterev ^{[4
]}

Lupu, Roxana ^{[5
]}

Teodorescu, Gabriela ^{[5
]}

Ciuleanu, Tudor E. ^{[6
]}

Pluzanski, Adam ^{[7
]}

机构：

[1] Univ Clin Resp & Allerg Dis, Med Oncol Dept, Golnik 4204, Slovenia

[2] Inst Oncol Ljubljana, Med Oncol Dept, Ljubljana 1000, Slovenia

[3] Sanador Oncol Ctr, Bucharest 010991, Romania

[4] MHAT Nadezhda, Dept Med Oncol, Sofia 1330, Bulgaria

[5] AstraZeneca Romania, Med Dept, Bucharest 013713, Romania

[6] Oncol Inst Prof Dr Ion Chiricuta, Med Oncol Dept, Cluj Napoca 400015, Romania

[7] Maria Sklodowska Curie Natl Res Inst Oncol, Lung Canc & Chest Tumours Dept, PL-02781 Warsaw, Poland

来源：

CURRENT ONCOLOGY | 2022年 / 29卷 / 08期

关键词：

real-world retrospective study; advanced non-small cell lung cancer; EGFR T790M mutation; TYROSINE KINASE INHIBITOR; OSIMERTINIB; RESISTANCE;

D O I：

10.3390/curroncol29080460

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The targeted therapy with tyrosine kinase inhibitors (TKIs) against the epidermal growth factor receptor mutation (EGFRm) in advanced non-small cell lung cancer (NSCLC) changed the treatment paradigm. REFLECT study (NCT04031898) explored EGFR/T790M testing and treatment patterns in EGFRm NSCLC patients receiving first- or second-generation (1G/2G) EGFR TKIs as front-line (1L) in eight countries. Pooled data from Central Eastern Europe (CEE) countries from this study (Bulgaria, Poland, Romania, Slovenia) are presented here. This physician-led chart review study was conducted in patients with confirmed-EGFRm NSCLC initiating 1L 1G/2G EGFR TKIs between 2015-2018. The CEE cohort included 389 patients receiving 1L erlotinib (37%), afatinib (34%), and gefitinib (29%). Overall, 320 (82%) patients discontinued 1L, and 298 (77%) progression events were registered. Median progression free survival on 1L TKIs was 14.0 (95% CI: 12.6-15.6) months. Median overall survival from 1L start was 26.6 (95% CI: 24.1-29.0) months. Attrition rate between 1L and next line was 30%. Among patients with 1L progression, 200 (67%) were tested for T790M and 58% were positive. This first CEE analysis of treatments and outcomes in EGFRm NSCLC patients highlights the importance of using the most efficacious therapies currently available in 1L to reduce attrition and improve patient outcomes.

引用

页码：5833 / 5845

页数：13

共 38 条

[11] Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer [J].

Halliday, Patrick R. ;

Blakely, Collin M. ;

Bivona, Trever G. .

CURRENT ONCOLOGY REPORTS, 2019, 21 (03)

[12] A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis? [J].

Han, Guang ;

Bi, Jianping ;

Tan, Wenyong ;

Wei, Xueyan ;

Wang, Xiaohong ;

Ying, Xiaofang ;

Guo, Xiaofang ;

Zhou, Xiaoyi ;

Hu, Desheng ;

Zhen, Weining .

ONCOTARGET, 2016, 7 (35) :56998-57010

[13] The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma [J].

Huang, Yen-Hsiang ;

Hsu, Kuo-Hsuan ;

Tseng, Jeng-Sen ;

Chen, Kun-Chieh ;

Hsu, Chia-Hung ;

Su, Kang-Yi ;

Chen, Jeremy J. W. ;

Chen, Huei-Wen ;

Yu, Sung-Liang ;

Yang, Tsung-Ying ;

Chang, Gee-Chen .

CANCER RESEARCH AND TREATMENT, 2018, 50 (04) :1294-1303

[14] Clinical characteristics of T790M-positive lung adenocarcinoma after resistance to epidermal growth factor receptor-tyrosine kinase inhibitors with an emphasis on brain metastasis and survival [J].

Joo, Jin Woo ;

Hong, Min Hee ;

Shim, Hyo Sup .

LUNG CANCER, 2018, 121 :12-17

[15] A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study [J].

Lee, Chung-Shien ;

Ahmed, Iman ;

Miao, Emily ;

Chung, Shirley ;

Patel, Khilna ;

Kohn, Nina ;

Seetharamu, Nagashree .

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (05) :1140-1151

[16] First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study [J].

Lorenzi, Martina ;

Ferro, Alessandra ;

Cecere, Fabiana ;

Scattolin, Daniela ;

Del Conte, Alessandro ;

Follador, Alessandro ;

Pilotto, Sara ;

Polo, Valentina ;

Santarpia, Mariacarmela ;

Chiari, Rita ;

Pavan, Alberto ;

Dal Maso, Alessandro ;

Da Ros, Valentina ;

Targato, Giada ;

Vari, Sabrina ;

Indraccolo, Stefano ;

Calabrese, Fiorella ;

Frega, Stefano ;

Bonanno, Laura ;

Conte, Pier Franco ;

Guarneri, Valentina ;

Pasello, Giulia .

ONCOLOGIST, 2022, 27 (02) :87-E115

[17] Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer [J].

Magios, Nikolaus ;

Bozorgmehr, Farastuk ;

Volckmar, Anna-Lena ;

Kazdal, Daniel ;

Kirchner, Martina ;

Herth, Felix J. ;

Heussel, Claus-Peter ;

Eichhorn, Florian ;

Meister, Michael ;

Muley, Thomas ;

Elshafie, Rami A. ;

Fischer, Jurgen R. ;

Faehling, Martin ;

Kriegsmann, Mark ;

Schirmacher, Peter ;

Bischoff, Helge ;

Stenzinger, Albrecht ;

Thomas, Michael ;

Christopoulos, Petros .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13

[18] OSIMERTINIB, A THIRD-GENERATION TYROSINE KINASE INHIBITOR TARGETING NON-SMALL CELL LUNG CANCER WITH EGFR T790M MUTATIONS [J].

McCoach, C. E. ;

Jimeno, A. .

DRUGS OF TODAY, 2016, 52 (10) :561-568

[19] Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer [J].

Mok, T. S. ;

Wu, Y. -L. ;

Ahn, M. -J. ;

Garassino, M. C. ;

Kim, H. R. ;

Ramalingam, S. S. ;

Shepherd, F. A. ;

He, Y. ;

Akamatsu, H. ;

Theelen, W. S. M. E. ;

Lee, C. K. ;

Sebastian, M. ;

Templeton, A. ;

Mann, H. ;

Marotti, M. ;

Ghiorghiu, S. ;

Papadimitrakopoulou, V. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (07) :629-640

[20] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Novello, S. ;

Barlesi, F. ;

Califano, R. ;

Cufer, T. ;

Ekman, S. ;

Levra, M. Giaj ;

Kerr, K. ;

Popat, S. ;

Reck, M. ;

Senan, S. ;

Simo, G. V. ;

Vansteenkiste, J. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2016, 27 :v1-v27

← 1 2 3 4 →